(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1742507

腎臓がん治療薬市場：がんタイプ別、治療法別、薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

Kidney Cancer Drugs Market Assessment, By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel, Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 245 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
腎臓がん治療薬市場：がんタイプ別、治療法別、薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年06月06日
発行: Markets & Data
ページ情報: 英文 245 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎臓がん治療薬の市場規模は、予測期間の2025年～2032年に5.80%のCAGRで拡大し、2024年の70億2,000万米ドルから2032年には110億2,000万米ドルに達すると予測されています。世界の腎臓がん治療薬市場は、高齢化、治療オプションの進歩、臨床的要因の組み合わせによって急速な成長を遂げています。米国がん協会の推計によると、2024年には約8万1,610人（男性5万2,380人、女性2万9,230人）が新たに腎臓がんと診断され、約1万4,390人（男性9,450人、女性4,940人）がこの病気で死亡しています。

腎臓がん治療薬市場は、いくつかの主な促進要因によって成長しています。まず、世界人口の高齢化とライフスタイルの変化に伴い、腎臓がんの罹患率が上昇し、治療を必要とする患者数も増加しています。最も注目すべきは、エビデンスに基づく治療選択肢が大幅に改善し、免疫療法や標的治療が最も使用される治療選択肢として台頭してきたため、患者の転帰が変化してきたことです。主な動向のひとつは、極めて有効な併用療法へのシフトであり、これらは標準治療の第一選択療法として認められています。

さらに、研究開発（R&D）への広範な投資は一貫して進化しており、その結果、新しいクラスのHIF-2a阻害剤のような革新的な薬剤のパイプラインが生まれています。また、経口療法は投与が容易であり、分子診断に基づく個別化治療への注目も高まっていることから、治療の有効性を高め、患者のコンプライアンスを促進する形で市場開拓が進んでいます。例えば、2025年2月、Telix Pharmaceuticals Limitedは、明細胞腎細胞がん（ccRCC）の治療薬としてTLX250-CDxのBLAをFDAが承認し、優先審議に付したと発表しました。

当レポートでは、世界の腎臓がん治療薬市場について調査し、市場の概要とともに、がんタイプ別、治療法別、薬剤クラス別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の腎臓がん治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • がんタイプ別
      • 腎細胞がん（RCC）
      • 移行上皮がん（TCC）
      • ウィルムス腫瘍（腎芽腫）
      • その他
    • 治療法別
      • 標的療法
      • 免疫療法
      • 化学療法
      • その他
    • 薬剤クラス別
      • 抗血管新生
      • モノクローナル抗体
      • mTOR阻害剤
      • インターロイキン
      • その他
    • 投与経路別
      • 経口
      • 静脈内
      • 皮下
    • 流通チャネル別
      • 病院
      • 専門薬局および小売薬局
      • その他
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米の腎臓がん治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の腎臓がん治療薬市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の腎臓がん治療薬市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の腎臓がん治療薬市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの腎臓がん治療薬市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場の促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制の枠組み

  • 臨床試験
  • 規制当局の承認

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Cipla Ltd.
    • F. Hoffmann-La Roche AG
    • Bayer AG
    • Exelixis, Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • UroGen Pharma Ltd.

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 3. Global Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 4. Global Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 5. Global Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 6. Global Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 7. Global Kidney Cancer Drugs Market Share (%), By Region, 2018-2032F
  • Figure 8. North America Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 9. North America Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 10. North America Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 11. North America Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 12. North America Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 13. North America Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 14. North America Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 15. United States Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. United States Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 17. United States Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 18. United States Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 19. United States Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 20. United States Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 21. Canada Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 22. Canada Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 23. Canada Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 24. Canada Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Canada Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Canada Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Mexico Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 28. Mexico Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 29. Mexico Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 30. Mexico Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 31. Mexico Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Mexico Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 34. Europe Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 35. Europe Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 36. Europe Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 37. Europe Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Europe Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. Europe Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 40. Germany Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. Germany Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 42. Germany Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 43. Germany Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 44. Germany Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 45. Germany Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 46. France Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. France Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 48. France Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 49. France Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 50. France Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 51. France Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Italy Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Italy Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 54. Italy Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 55. Italy Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 56. Italy Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 57. Italy Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 58. United Kingdom Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 59. United Kingdom Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 60. United Kingdom Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 61. United Kingdom Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. United Kingdom Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. United Kingdom Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Russia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Russia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 66. Russia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 67. Russia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 68. Russia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 69. Russia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 70. Netherlands Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 71. Netherlands Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 72. Netherlands Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 73. Netherlands Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 74. Netherlands Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 75. Netherlands Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 76. Spain Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 77. Spain Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 78. Spain Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 79. Spain Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 80. Spain Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 81. Spain Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 82. Turkey Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. Turkey Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 84. Turkey Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 85. Turkey Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 86. Turkey Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 87. Turkey Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 88. Poland Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 89. Poland Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 90. Poland Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 91. Poland Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 92. Poland Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 93. Poland Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. South America Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. South America Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 96. South America Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 97. South America Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 98. South America Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. South America Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. South America Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 101. Brazil Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. Brazil Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 103. Brazil Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 104. Brazil Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 105. Brazil Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 106. Brazil Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 107. Argentina Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 108. Argentina Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 109. Argentina Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 110. Argentina Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 111. Argentina Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 112. Argentina Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 113. Asia-Pacific Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 114. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 115. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 116. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 117. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 118. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 119. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 120. India Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. India Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 122. India Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 123. India Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 124. India Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 125. India Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. China Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. China Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 128. China Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 129. China Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 130. China Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 131. China Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 132. Japan Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 133. Japan Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 134. Japan Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 135. Japan Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 136. Japan Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 137. Japan Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 138. Australia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 139. Australia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 140. Australia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 141. Australia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 142. Australia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 143. Australia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 144. Vietnam Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 145. Vietnam Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 146. Vietnam Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 147. Vietnam Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 148. Vietnam Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 149. Vietnam Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 150. South Korea Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 151. South Korea Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 152. South Korea Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 153. South Korea Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 154. South Korea Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 155. South Korea Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 156. Indonesia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 157. Indonesia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 158. Indonesia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 159. Indonesia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 160. Indonesia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. Indonesia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. Philippines Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 163. Philippines Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 164. Philippines Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 165. Philippines Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 166. Philippines Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 167. Philippines Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 168. Middle East & Africa Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 169. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 170. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 171. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 172. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 173. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 174. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 175. Saudi Arabia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 176. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 177. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 178. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 179. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 180. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 181. UAE Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 182. UAE Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 183. UAE Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 184. UAE Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 185. UAE Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 186. UAE Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 187. South Africa Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 188. South Africa Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 189. South Africa Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 190. South Africa Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 191. South Africa Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 192. South Africa Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 193. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 194. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13253

Global kidney cancer drugs market is projected to witness a CAGR of 5.80% during the forecast period 2025-2032, growing from USD 7.02 billion in 2024 to USD 11.02 billion in 2032. The global kidney cancer drugs market experiences rapid growth, driven by a combination of aging population, advancement in therapeutic option and clinical factors. As per the American Cancer Society's estimates in 2024

around 81,610 new cases of kidney cancer (52,380 males and 29,230 females) are diagnosed and about 14,390 people (9,450 men and 4,940 women) died from this disease.

The kidney cancer drug market is seeing growth owing to several principal drivers. First, as the global population continues to age and lifestyle factors change, the incidence of kidney cancer is rising, with the number of patients in need of treatment also increasing. Most notably, the outcomes of patients have changed as evidence-based treatment options have improved significantly with the rise of immunotherapy, and targeted therapies as the most used treatment options. One of the main trends is a shift toward the use of extremely effective combination therapies, which are recognized as standard of care first line therapy.

Moreover, the extensive investment in Research and Development (R&D) is consistently evolving, resulting in a pipeline of innovative agents such as new classes of HIF-2a inhibitors. Also, with the ease of administration of oral therapies and an increased focus on individualized therapy based on molecular diagnostics, both majorly drive market development in a way that enhances the efficacy of treatment and promotes patient compliance. For instance, in February 2025, Telix Pharmaceuticals Limited declared that the FDA has approved and given priority consideration to the BLA of TLX250-CDx for the treatment of clear cell renal cell carcinoma (ccRCC).

Advancement in Diagnostic Technology

Developments in advanced diagnostic technologies are fundamentally driving growth in the global kidney cancer drugs market by creating more opportunities for early detection, better tumor characterization, and personalized treatment approaches. Advancements in imaging technologies such as AI-enriched CT/MRI and new PET-CT tracers enable the identification of smaller tumors that improve patient eligibility for systemic therapies. Additionally, liquid biopsies and genomic profiling enable the non-invasive detection of mutations and help to refine the use of targeted therapies and immunotherapy based on individual patient biomarkers. AI-enabled diagnostic platforms aim to optimize treatment selection based on prediction of drug responses on a given patient, which mitigates the burden of trial-and-error prescribing and allows for greater adoption of high-efficacy treatment regimens. Furthermore, sequential combination therapies, digitized multi-omics, and AI diagnostic capabilities will further attract patients and drive demand in new areas of precision medicine.

Additionally, leading research organizations are focusing on developing new technologies to improve the quality of care provided to the patient population. For instance, according to an article published in American Society of Clinical Oncology (ASCO) in February 2023, the Phase 3 ZIRCON trial assessed the use of Zr-DFO-girentuximab PET/CT imaging to detect and characterize clear-cell renal cell carcinoma (ccRCC).

Hospitals Holds Largest Distribution Channels of Drugs

There are various key factors contributing to the dominating position of hospitals segment in the kidney cancer drugs market. One reason is the treatment for kidney cancer may include complicated regimens in terms of dosage, handling, storage requiring special consideration, as well as requiring thorough ongoing monitoring of side effects, due to the use of immunotherapies and targeted therapies. Research suggests the complicated treatment regimen can be managed more effectively by hospital-based oncology departments with highly skilled doctors and specialty oncology pharmacists on staff as well as nursing staff. They provide a controlled setting for intravenous drug administration, administer possible drug interactions, and offer extensive patient education and support care. Moreover, the exorbitant prices of most new kidney cancer drugs most often require dispensing by hospital pharmacies, which also enjoy bulk purchasing power and established supply chains for repeated access to these potentially life-saving drugs for patients receiving intensive cancer treatment. For instance, in January 2024, Fox Chase Cancer Center invested in a new study to demonstrate that immune checkpoint inhibitor-based therapy (ICI), a form of immunotherapy, is an equally effective frontline therapy for Black and white patients with metastatic kidney cell carcinoma.

The expansion of the Asia-Pacific kidney Cancer Medication Market

The renal cancer drug market is spearheaded in the Asia-Pacific (APAC) region for many reasons, as examples, the increasing incident and prevalence of kidney cancer linked to aging and lifestyles has positively contributed to a larger patient pool. Additionally, growing investments in the healthcare infrastructure and increased public understanding have improved early detection and significant demand for newer treatments. Patients now have greater access to pricey new medicines thanks to APAC's robust economic growth, rising healthcare costs, and expanding insurance coverage. Personalized medicine, such as targeted treatments and immunotherapies, is a major focus in the region, as well as high R&D and pharma investment, propels the creation and adoption of innovative medicines, But APAC's market does come with significant challenges. The exorbitant price of new kidney cancer medicines is a major hurdle for most patients, affecting accessibility. Varying and sometimes complex regulatory approvals in different nations have the potential to slow market access for innovative drugs.

Additionally, for market expansion in Asia-Pacific region in March 2025 companies like HUTCHMED (China) Limited and Innovent Biologics,Inc. jointly announced that FRUSICA-2 phase II/III clinical trial study in China for advanced renal cell carcinoma.

Impact of U.S. Tariffs on Kidney Cancer Drugs Market

The impact from recent the recent U.S. tariffs which targeted pharmaceutical import from China and India and other major suppliers. The tariffs cause an increase in production expenses which might raise drugs prices while creating potential disruptions in the supply chains. The thin profits margin of generic drugs manufacturer would intensify because of these added expenses which could lead to decreased competition and reduced treatment options. The global pharmaceutical export market faces economic trouble because of challenging condition in Ireland and South Korea. The possibility of companies moving manufacturing operation back to the United States may create temporary drugs shortages that will affect patient worldwide by disrupting their access to treatment and negatively impacts their outcomes.

Key Players Landscape and Outlook

There is an intense competition in the kidney cancer drugs market from established pharmaceutical companies and new start-up biotech firms involved in research and development. Additionally, the kidney cancer drugs market is projected to continue to grow in part due to new advances in immunotherapy, targeted therapy and increased combination or multi-modality regimens. The focus on more effective treatments with personalization and improved safety profiles will continue to enable patient improvements and quality of life. Companies like Novartis AG and Merck & Co., Inc. are continuously working on new innovation for the renal cell treatment.

According to the news published on Clinical trials Arena in October 2024, Arcus Biosciences Inc. announced a clinical trial collaboration with AstraZeneca plc to evaluate the combination of casdatifan (AB521) and volrustomig in ccRCC patients. Casdatifan is an investigational HIF-2a inhibitor from Arcus and volrustomig is an investigational PD-1/CTLA-4 bispecific antibody from AstraZeneca.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Cancer Type
      • 5.2.1.1. Renal Cell Carcinoma (RCC)
      • 5.2.1.2. Transitional Cell Cancer (TCC)
      • 5.2.1.3. Wilms Tumor (Nephroblastoma)
      • 5.2.1.4. Others
    • 5.2.2. By Therapy
      • 5.2.2.1. Targeted Therapy
      • 5.2.2.2. Immunotherapy
      • 5.2.2.3. Chemotherapy
      • 5.2.2.4. Other Therapies
    • 5.2.3. By Drug Class
      • 5.2.3.1. Anti-Angiogenesis
      • 5.2.3.2. Monoclonal Antibodies
      • 5.2.3.3. mTOR Inhibitors
      • 5.2.3.4. Interleukins
      • 5.2.3.5. Other Drug Classes
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Intravenous
      • 5.2.4.3. Subcutaneous
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital
      • 5.2.5.2. Specialty and Retail Pharmacies
      • 5.2.5.3. Others
    • 5.2.6. By Region
      • 5.2.6.1. North America
      • 5.2.6.2. Europe
      • 5.2.6.3. Asia-Pacific
      • 5.2.6.4. South America
      • 5.2.6.5. Middle East and Africa
    • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Cancer Type
    • 5.3.2. By Therapy
    • 5.3.3. By Drug Class
    • 5.3.4. By Route of Administration
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Cancer Type
      • 6.2.1.1. Renal Cell Carcinoma (RCC)
      • 6.2.1.2. Transitional Cell Cancer (TCC)
      • 6.2.1.3. Wilms Tumor (Nephroblastoma)
      • 6.2.1.4. Others
    • 6.2.2. By Therapy
      • 6.2.2.1. Targeted Therapy
      • 6.2.2.2. Immunotherapy
      • 6.2.2.3. Chemotherapy
      • 6.2.2.4. Other Therapies
    • 6.2.3. By Drug Class
      • 6.2.3.1. Anti-Angiogenesis
      • 6.2.3.2. Monoclonal Antibodies
      • 6.2.3.3. mTOR Inhibitors
      • 6.2.3.4. Interleukins
      • 6.2.3.5. Other Drug Classes
    • 6.2.4. By Route of Administration
      • 6.2.4.1. Oral
      • 6.2.4.2. Intravenous
      • 6.2.4.3. Subcutaneous
    • 6.2.5. By Distribution Channel
      • 6.2.5.1. Hospital
      • 6.2.5.2. Specialty and Retail Pharmacies
      • 6.2.5.3. Others
    • 6.2.6. By Country Share
      • 6.2.6.1. United States
      • 6.2.6.2. Canada
      • 6.2.6.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Kidney Cancer Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Cancer Type
          • 6.3.1.2.1.1. Renal Cell Carcinoma (RCC)
          • 6.3.1.2.1.2. Transitional Cell Cancer (TCC)
          • 6.3.1.2.1.3. Wilms Tumor (Nephroblastoma)
          • 6.3.1.2.1.4. Others
        • 6.3.1.2.2. By Therapy
          • 6.3.1.2.2.1. Targeted Therapy
          • 6.3.1.2.2.2. Immunotherapy
          • 6.3.1.2.2.3. Chemotherapy
          • 6.3.1.2.2.4. Other Therapies
        • 6.3.1.2.3. By Drug Class
          • 6.3.1.2.3.1. Anti-Angiogenesis
          • 6.3.1.2.3.2. Monoclonal Antibodies
          • 6.3.1.2.3.3. mTOR Inhibitors
          • 6.3.1.2.3.4. Interleukins
          • 6.3.1.2.3.5. Other Drug Classes
        • 6.3.1.2.4. By Route of Administration
          • 6.3.1.2.4.1. Oral
          • 6.3.1.2.4.2. Intravenous
          • 6.3.1.2.4.3. Subcutaneous
        • 6.3.1.2.5. By Distribution Channel
          • 6.3.1.2.5.1. Hospital
          • 6.3.1.2.5.2. Specialty and Retail Pharmacies
          • 6.3.1.2.5.3. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Amgen Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Pfizer Inc.
    • 21.3.3. Novartis AG
    • 21.3.4. Cipla Ltd.
    • 21.3.5. F. Hoffmann-La Roche AG
    • 21.3.6. Bayer AG
    • 21.3.7. Exelixis, Inc.
    • 21.3.8. Bristol-Myers Squibb Company
    • 21.3.9. Merck & Co., Inc.
    • 21.3.10. UroGen Pharma Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer